Fill in the form to access the recording


Transform Biomedicine and Drug Discovery Through Innovative Proteomics

With proteomic experts from AbbVie and University of Göttingen



Proteomics is pivotal in bridging the gap between basic biomedical research and the development of new, targeted therapeutics.

Hidden causes of diseases can be revealed by proteomics, which is instrumental in identifying new biomarkers and therapeutic targets to support drug discovery.

In this webinar, you’ll hear from Christof Lenz, PhD, about the importance of analyzing tissue samples in biomedical proteomics, particularly for understanding the molecular basis of cardiac diseases. Our second speaker, Greg Potts, PhD, will showcase how chemoproteomics, in combination with data-independent acquisition, speeds up drug discovery.

You’ll also gain insights into innovative strategies for boosting proteomic analysis through standardized sample prep technologies and state-of-the-art mass-spectrometry-based workflows.

Attend this webinar to:

  • Learn how optimized proteomic sample preparation can be a game-changer in biomedical research
  • Gain insights into cardiac disease mechanisms through tissue proteomics
  • Explore how modern chemoproteomic approaches and MS acquisition techniques advance drug discovery
  • Discover how standardized and efficient sample prep can help obtain reliable data while scaling proteome study size

Agenda and Talks

  • Welcome and intro
    Silvia Würtenberger, PreOmics GmbH
  • Spatially resolved cardiac proteomics, and a BeatBox
    Christof Lenz, Director Core Facility Proteomics, University Medical Center, Göttingen, Germany
  • Data Independent Acquisition (DIA) mass spectrometry for quantifying drug-target engagement in the pharmaceutical industry
    Greg Potts, Senior Scientist, Technology and Therapeutic Platforms, AbbVie
  • Q&A

Meet our speakers

Christof Lenz, PhD

Gregory Potts, PhD

Christof Lenz is the Head of the Core Proteomics Facility at the University Medical Center of Göttingen and also teaches Cardiovascular Science students. His research focuses on applied omics technologies to understand cardiac desease mechanisms.  

Greg Potts obtained a BSc in Chemistry from the University of Illinois Urbana-Champaign in 2011. He then earned his PhD in Chemistry from the University of Wisconsin-Madison in 2016 under the mentorship of Professor Josh Coon. Greg began his career with Thermo Fisher Scientific before joining AbbVie in the Chemical Biology and Mass Spectrometry Technologies group in 2017. 

Copyright ©2023 All Rights Reserved

PreOmics GmbH
Am Klopferspitz 19 

D-82152 Planegg/Martinsried

Phone: +49-89-2314163-0

Fax: +49-89-2314163-99